Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm

Panpan Zhang\textsuperscript{1} | Zhongwu Li\textsuperscript{2} | Jie Li\textsuperscript{3} | Jian Li\textsuperscript{3} | Xiaotian Zhang\textsuperscript{3} | Zhihao Lu\textsuperscript{3} | Yu Sun\textsuperscript{2} | Yan Li\textsuperscript{3} | Jun Zhou\textsuperscript{3} | Xicheng Wang\textsuperscript{3} | Zhi Peng\textsuperscript{3} | Lin Shen\textsuperscript{3} | Ming Lu\textsuperscript{3}

\textsuperscript{1}Department of Early Drug Development Centre, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China
\textsuperscript{2}Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China
\textsuperscript{3}Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China

Correspondence
Ming Lu, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Fu-Cheng Road 52, Hai-Dian District, Beijing 100142, China.
Email: qiminglu_mail@126.com

Funding information
The study was supported by the National Key Research and Development Program of China (No. 2017YFC0908400, 2017YFC1308900) and the third round of public welfare development and reform pilot projects of Beijing Municipal Medical Research Institutes (Beijing Medical Research Institute, 2019-1).

Abstract

Objective: Owing to its rarity and heterogeneity, the biological behavior and optimal therapeutic management of mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) have not been established. Herein, we aimed to evaluate the clinicopathological characteristics and metastatic patterns of MiNEN.

Methods: Continuous clinicopathological data of MiNEN patients treated at our hospital were retrospectively collected and analyzed.

Results: This study had enrolled 169 patients since January 2010 to January 2020. Pathological components were assessed in 129 patients with MiNEN (76.3%), and a focal (non-)neuroendocrine component was observed in 40 patients (23.7%; <30% of the tumor). Among the enrolled patients, 80 underwent surgical removal of the primary tumor and lymph nodes (LNs), and 34 with distant metastasis underwent biopsy of both primary tumor and metastatic lesions. In patients with LN metastasis, 68.8% (55/80) exhibited a pure component of either neuroendocrine (NE) or adenocarcinoma/squamous carcinoma (AS) in metastatic LNs, while 20% (16/80) showed different components in different LNs, and only 11.2% (9/80) showed both NE and AS components in the same LN. In patients with distant metastases, 26.5% (9/34) possessed coexisting NE and AS components in the distant metastases, 70.6% (24/34) were regarded as a pure NE component, and 2.9% (1/34) were comprised of a pure AS component.

Conclusion: Lymph node and distant metastases exhibited distinct metastatic patterns in patients with MiNEN. The major pathological component in regional LNs may have influenced the proportion of the two components within the primary tumor, but distant metastases were dominated by the NE component.

Panpan Zhang and Zhongwu Li contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
INTRODUCTION

Gastroenteropancreatic tumors involving both exocrine and neuroendocrine components are exceedingly rare and were first reported by Cordier in 1924. These two components can exhibit various morphological patterns and form mixed neoplasms, which are classified into three categories: collision, composite, and amphicrine tumors. One subtype of neuroendocrine carcinoma with both epithelial and neuroendocrine cells, the mixed adenoneuroendocrine carcinoma (MANEC) was defined by the World Health Organization (WHO) at 2010, with the epithelial and neuroendocrine component each comprising at least 30% of the tumor. The term MANEC, however, does not adequately convey the morphological heterogeneity of the disease and has caused confusion in the literature. In the latest version of WHO classification 2017, MANEC was renamed as mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN). Owing to its rarity, morphologic diversity, and distinct primary origins, the origin and classification of this neoplasm are not well-defined, and the optimal therapeutic management has not yet been established. It remains unclear whether MiNEN should be treated as an adenocarcinoma or a neuroendocrine neoplasm. To gain a better understanding of the heterogeneous nature of MiNEN and to preliminarily establish guidelines for reasonable clinical management, we retrospectively investigated the clinicopathological features and metastatic patterns of MiNEN treated at our center. To our knowledge, this is one of the largest single-center MiNEN cohorts to date, as well as the first extended report concerning metastatic characteristics of this rare tumor type. Findings from this study can contribute to better understanding the biological behavior of this disease, thereby facilitate better treatment decisions.

PATIENTS AND METHODS

Patients

We retrospectively collected clinical, pathological and survival data of patients diagnosed with gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) at our hospital from January 2010 to January 2020. The pathology database was further explored to identify patients with a pathological diagnosis of MANEC or MiNEN, defined as each tumor component accounting for at least 30% of the tumor, based on the 2010 and 2017 WHO classifications. Patients with two pathological components who failed to meet the criteria (each component accounting for less than 30% of the tumor) were also included in the study. Tumor stages were assigned according to the AJCC 8th Edition Cancer Staging system.

For the analysis of pathological component patterns in lymph nodes, we enrolled patients who underwent surgery for primary tumor and lymph node dissection. For the analysis of distant metastases, those who had distant metastasis at diagnosis or recurrence and underwent biopsy of both primary and metastatic lesions were enrolled. The flow diagram of the study is shown in Figure 1. This study was approved by our institutional research ethics board. All enrolled patients provided written consent for usage of their information and specimens stored in the hospital database for research.

Diagnosis and classification

According to the 2017 WHO classification, MiNEN is defined as a malignant tumor containing at least 30% of both glandular epithelial cells and neuroendocrine cells. Patients with tumors that had two components but did not meet the criteria of MiNEN were also enrolled, and their tumors were assigned to either a neuroendocrine (NE)-dominant type or an adenocarcinoma/squamous carcinoma (AS)-dominant type according to the tumor dominance. For each case, all slides of the primary tumor, regional lymph nodes and/or distant metastases were reviewed, and the following parameters were collected: the proportion and histologic subtypes of the two components, the number of mitoses per 10 high-power fields (HPFs), the Ki67 index of the neuroendocrine component, and the number and content of metastasis. All pathological findings were reviewed and confirmed by two pathologists independently.

Based on the histological type, regional lymph nodes and/or distant metastases, each tissue sample was assigned into one of the following groups: (1) tissues with a neuroendocrine carcinoma or adenocarcinoma (or squamous carcinoma) component only; (2) tissues exhibiting coexistence of adenocarcinoma (or squamous carcinoma) and neuroendocrine carcinoma within one metastatic lesion; and (3) tissues with distinct metastatic lesions showing either an adenocarcinoma (or squamous carcinoma) or a neuroendocrine carcinoma component exclusively.

Statistical analysis

The Student's t test, χ2 test (or Fisher's exact test) and the Mann-Whitney test were used to analyze the clinicopathological
characteristics of the patients. Overall survival (OS) time was measured from the date of initial diagnosis until the date of death or the date of the last known follow-up. The log-rank test was used to compare survival rates. Statistical tests used two-tailed P values, and $p < 0.05$ was considered statistically significant. All statistical analyses were performed with SPSS (version 25; IBM).

3 | RESULTS

3.1 | Clinicopathological characteristics

The clinicopathological data of patients treated at our hospital from January 2010 to January 2020 were reviewed, and data of 1,857 patients with a pathologic diagnosis of GEP-NEN were retrieved. Among these patients, 169 with both glandular epithelial and neuroendocrine cells were identified, and 129 of these patients (76.3%) were classified as patients with MiNEN, in line with the 2017 WHO classification. In the remaining 40 (23.7%) cases, a focal (non-) neuroendocrine component (<30% of the tumor tissue) was observed. Among the enrolled patients, 27/169 (16%) were diagnosed by biopsy only, and the rest underwent operative pathological diagnosis. The primary tumors were identified in the following sites: the stomach (104, 61.5%), colorectal (21, 12.4%), esophagus (19, 11.2%), duodenum (7, 4.1%), biliary tract (6, 3.6%), pancreas (5, 3%), and other sites (7, 4.1%). The clinicopathological characteristics of the entire cohort (n = 169) are shown in Table 1. For AS component, there were 22 cases (13.0%) of squamous carcinoma and 147 (87.0%) adenocarcinomas of varying degrees of differentiation. For the NE component, there were 6 patients (3.6%) with neuroendocrine tumor (NET) and 163 patients (96.4%) with neuroendocrine carcinoma (NEC). Patients in stage I-II, III and IV exhibited 3-year survival rates of 82%, 41% and 25%, respectively; and their median OS (mOS) were not available (NA), 28.5 and 10.7 months ($p < 0.0001$), respectively. There was no difference in survival outcomes among patients with MiNEN, AS-dominant and NE-dominant tumors ($p = 0.91$). The mOS of patients with primary esophageal tumors (16.2 months) or colorectal primary tumors (23.3 months) was shorter than that of patients with primary stomach tumors (28.7 months) and primary tumors at other primary sites (NA), but the difference was not statistically significant ($p = 0.14$) (Figure 2).

Detailed pathological evaluation of the components of lymph node metastasis was available in 80 patients who underwent the primary tumor and regional lymph node resection. In this cohort, 60 patients were classified as MiNEN, 18 were NE-dominant type (>70% of tumor tissue), and 2 were AS-dominant type. There were 34 patients who had distant metastases at diagnosis or recurrence and biopsies of the metastatic lesion were available for evaluation. This cohort contained 25 patients with MiNEN, 6 patients with NE-dominant type tumors and 3 patients with AS-dominant type tumors.

3.2 | Lymph node metastatic patterns

This cohort included 80 patients, and 55 patients (68.8%) exhibited lymph nodes with a pure component, 16 patients (20%) had different components in different LN, and only 9 patients (11.2%) had a mixture of two components coexisting in the same lymph node. In cases with a pure component in the lymph nodes (n = 55), 13 had a pure AS component and 42 had a pure NE component. The metastatic patterns of the lymph nodes are shown in Table 2.

In these 80 patients, a total of 453 lymph node metastases were identified, including 119 (26.3%) with a single AS component, 294 (64.9%) with pure NE component and 40 (8.8%) with a mixture of components containing NE and AS. Lymph
node metastatic patterns may be associated with the proportion of two components within the primary tumors (Figure 3). Subgroups were classified by the percentage of NE component (<30%, 30%-50%, >50% ≤70% and >70%) within the primary tumor sites. The ratio of lymph nodes with a single AS component decreased to 66.7%, 42.1%, 21.7% and 6.3%; while the proportion with a pure NE component increased to 33.3%, 41.0%, 76.8% and 88.1%, respectively.

### 3.3 Distant metastatic patterns

Among the 34 patients with distant metastases at diagnosis or recurrence, 24 metastatic tumors (70.6%) consisted of a single NE component (1 NET G2 and 23 poorly differentiated NEC), 9 patients (26.5%) showed coexistence of both NE and AS components, and only 1 patient (2.9%) had a pure adenocarcinoma component. There were 24 patients with liver metastases in this cohort, 19 of which comprised of a pure NE component, 4 were made up by a mixture of both AS and NE components, and only 1 with a pure adenocarcinoma component. Among the 8 patients with peritoneal or supraclavicular lymph node metastases, 4 possessed a pure NE component, and the remaining lymph node metastases demonstrated the properties of a mixture of both AS and NE components. The remaining 2 metastases were in the lung (n = 1), containing both AS and NE components, and in the brain (n = 1), with a pure NE component, respectively.

As for the pathological degree of differentiation, in patients with a primary tumor with a poorly differentiated AS component (n = 13), the metastatic lesions were invaded by a pure NE component in 10 cases, by a pure AS component in 1 case, and by mixed components in 2 cases. Among patients with well or moderately differentiated AS components (n = 21), 14 had a pure NE component within distant metastasis, while the remaining 7 patients had distant lesions revealing coexistence of both NE and AS components.

We also enrolled 9 patients with a focal (non-)neuroendocrine component less than 30% of the tumor; these patients presented a domination by NE (n = 6) or AS (n = 3) in the primary tumors. In 8 of these patients (88.9%), distant metastases showed a pure NE component, while the coexistence of both AS and NE components were observed in 1 patient. Of note, in all 3 cases with a NE component accounting for less than 30% of the primary tumor, metastases were invaded by a pure NE component (Table 3).

### 4 DISCUSSION

Due to the rarity and heterogeneity of MiNEN, its location-specific clinical features, pathological classification, and metastatic patterns are not well understood. In the present study, the most common primary site of MiNEN was the stomach and colorectum. When defining MiNEN, the 2017 and 2019 versions of the WHO classification criteria used more general
terms to include histological variants of squamous carcinoma, pancreatic ductal adenocarcinoma or low-grade NET as one or both components. In this study, the majority of exocrine components observed were adenocarcinoma, and the majority of NE components were NEC. Therefore, MiNEN is an aggressive entity with poorly differentiated NEC components in most cases and is thus associated with poor prognosis. Furthermore, only 16% of the patients (27/169) were diagnosed by biopsy only; the diagnosis of the rest of the patients was confirmed through postoperative pathology. Thus, it is difficult to diagnose MiNEN only with biopsy, and special attention should be paid to the potential bias in evaluating biopsy specimens. Therefore, it is recommended that pathological specimens should be evaluated after the surgical removal of the entire neoplasm.

Current WHO classification criteria requires that each component of MiNEN accounts for at least 30% of the entire tumor, which was originally proposed by Lewin in 1987. It
was speculated that the prognosis of MiNEN was affected by major histological factors rather than the components accounting for <30% of the entire tumor. Currently, the threshold in this definition becomes controversial and has caused confusion in therapeutic management of these neoplasms. In the literature, Jiang et al. set the volume threshold as ≥20% for the NE component. In addition, Park et al. indicated that survival of patients with a NE component of greater than 10% was poorer than that of their counterparts, but no survival difference was observed between NEC and MiNEN patients. In our study, no significant survival difference was observed among MiNEN, NEC-dominated and AS-dominated patients. However, we found that even if the NE component comprised less than 30% of the primary tumor, a pure NE component could still appear in distant metastases. Due to the rarity of such mixed neoplasms, our findings are valuable and highlight the need for optimal thresholds and criteria for assessing the biological behavior and treatment response. In clinical management, the percentage of each component must be clarified; and for biopsy specimens with NE component <30%, the heterogeneity of the neoplasm needs to be considered to develop a comprehensive treatment plan.

MiNEN is frequently diagnosed with extensive lymph node and liver metastasis, which is the most important risk factor for poor prognosis. However, there is currently no consensus on the metastatic patterns in the literature. In the current study, MiNEN cases were grouped according to the ratio of primary tumor components, and the metastatic lymph nodes and distant lesions of each patient were evaluated for their pathological components. As the proportion of the NE component in the primary tumor increased, the ratio of positive lymph nodes with pure NE invasion in each
argue that a minor poorly differentiated NEC component can
component within the tumor, regardless of proportion. They
proposed that treatment should target the more aggressive
poor prognostic factor in patients with MiNEN. It was hy-
(>50%) of a high-grade NE component as an independent
proposed that the prognosis is influenced by the predom-
adenocarcinoma component. 7-10 Watanabe et al. 11 reported
by a neuroendocrine carcinoma component rather than an
metastasis, and tumors with an NE component comprising less
30% volume of the mixed tumors could still occur in
distant metastasis and exert an impact on the prognosis.
The cause of different metastatic patterns of lymph nodes and
distant metastases, as well as the intrinsic forces that
drives the two components to metastasize, remain unclear.
An increasing number of pathologists have made efforts to
identify the histological origin of the mixed carcinoma. It is
proposed that MiNEN originates from single endoderm plu-
rupotent stem cells, which are affected by hormones, the mi-
croenvironment and unstable genomes during the process of
tumor development, resulting in two-way or multidirectional
differentiation.16 However, another theory proposed that the
two components of MiNEN descend from two different cell
linages.17 However, the oncogenesis and malignant behavior
in this tumor type are far from settled. Molecular studies
have reported that NE components share molecular abnor-
malities with their adenocarcinoma counterparts while also
displaying additional alterations.18-20 In the present study, we
found that distant lesions were usually invaded by pure NE or
mixed components. By comparison of synchronic and non-
synchronic metastases, we found that the proportion of coex-
isting components increased in lesions that relapsed during
the course of disease. Further studies should focus on mo-
lecular mechanisms to reveal the intrinsic driving forces of
metastatic patterns and to identify the pathogenic pathways
involved in the carcinogenic progress.

TABLE 3 Correlation of the percentage of NE component in
primary tumor sites with a distant metastatic pattern in 34 patients

| Characteristics, n (%) | Pure NE | Pure AS | Mixed component |
|------------------------|---------|---------|-----------------|
| Synchronic             | 13 (65) | 1 (5)   | 6 (30)          |
| Non-synchronic         | 11 (78.6) | 0 (0)  | 3 (21.4)        |
| NE proportion          |         |         |                 |
| <30%                   | 3 (100) | 0 (0)   | 0 (0)           |
| 30%-50%                | 5 (55.6) | 1 (11.1) | 3 (33.3)        |
| >50% ≤70%              | 11 (68.8) | 0 (0)  | 5 (31.2)        |
| >70%                   | 5 (83.3) | 0 (0)   | 1 (16.7)        |
| Metastatic sites       |         |         |                 |
| Liver                  | 19 (79.2) | 1 (4.3) | 4 (17.4)        |
| Lung or brain          | 1 (50)  | 0 (0)   | 1 (50)          |
| Distant lymph nodesa   | 4 (50)  | 0 (0)   | 4 (50)          |
| Total                  | 24 (70.6) | 1 (2.9) | 9 (26.5)        |

AS, adenocarcinoma/squamous carcinoma; LN, lymph node; n, number of patients; NE, neuroendocrine.
aDistant lymph nodes indicate supraclavicular or peritoneal nodules.

group also increased. Previous case reports have revealed that
lymph nodes and liver metastases are usually invaded by a neuroendocrine carcinoma component rather than an
adenoacarcinoma component.7-10 Watanabe et al.11 reported
that pathological analysis of metastasized tissue in 9 patients
with recurrent MiNEN demonstrated an NE component in
5 patients and an AC component in 4 patients. In our study,
the results revealed that both regional lymph nodes and dis-
tant metastases were primarily invaded by one component.
However, distant metastases were primarily invaded by the
NE component. Moreover, 26.5% of patients had a mixture
of both AS and NE components; and the pure exocrine com-
ponent rarely metastasized to distant organs. Therefore, the
proportion of components within the primary lesion provide
limited information regarding adjuvant treatment regimen
choices for MiNEN patients. Meanwhile, the presence of
an NE component in the original neoplasms increases the
chance of recurrence in distant metastases.

In clinical practice, the biological behavior and prognos-
tic factors of MiNEN are controversial. At present, there are
two main opinions in the field: (1) It has been proposed that
the volume proportion of the two components determines the
clinical course of MiNEN. Chen et al12 regarded high volume
(>50%) of a high-grade NE component as an independent
poor prognostic factor in patients with MiNEN. It was hy-
pothesized that the prognosis is influenced by the predom-
inant histological component rather than the one accounting
for <30% of the entire neoplasm.13 (2) Other researchers have
proposed that treatment should target the more aggressive
component within the tumor, regardless of proportion. They
argue that a minor poorly differentiated NEC component can
impact prognosis, as recent studies have demonstrated that
the prognosis of MiNEN is defined by the more invasive com-
ponent.14,15 As previous research data have been extremely
heterogeneous in terms of primary tumor site, disease stage
and type of information provided, our study is the largest ret-
rospective analysis of GEP MiNEN examining lymph node
distant metastatic patterns. Our results revealed that there
is a clear correlation between regional lymph node metastasis
component and the proportion of each component within the
primary tumor. Of note, the NE component tended to metas-
tasize, and tumors with an NE component comprising less
than 30% volume of the mixed tumors could still occur in
distant metastasis and exert an impact on the prognosis.

The cause of different metastatic patterns of lymph nodes and
distant metastases, as well as the intrinsic forces that
drives the two components to metastasize, remain unclear.
An increasing number of pathologists have made efforts to
identify the histological origin of the mixed carcinoma. It is
proposed that MiNEN originates from single endoderm plu-
rupotent stem cells, which are affected by hormones, the mi-
croenvironment and unstable genomes during the process of
tumor development, resulting in two-way or multidirectional
differentiation.16 However, another theory proposed that the
two components of MiNEN descend from two different cell
linages.17 However, the oncogenesis and malignant behavior
in this tumor type are far from settled. Molecular studies
have reported that NE components share molecular abnor-
malities with their adenocarcinoma counterparts while also
displaying additional alterations.18-20 In the present study, we
found that distant lesions were usually invaded by pure NE or
mixed components. By comparison of synchronic and non-
synchronic metastases, we found that the proportion of coex-
isting components increased in lesions that relapsed during
the course of disease. Further studies should focus on mo-
lecular mechanisms to reveal the intrinsic driving forces of
metastatic patterns and to identify the pathogenic pathways
involved in the carcinogenic progress.

To date, no clinical practice guidelines have been devel-
oped, and only a limited number of case series on MiNEN
have been published. Surgical resection is considered as the
only curative treatment, and adjuvant chemotherapy is rec-
ommended due to the high recurrence rate of these tumors.21
MiNEN is often diagnosed at an advanced stage as a result of
its aggressive nature and may not be suitable for curative
resection. In such cases, chemotherapy with cytotoxic drugs
plays a primary role in the treatment. However, it is contro-
versial to establish universal guidelines for adjuvant and pal-
liative chemotherapy in MiNEN patients. In our study, we
found that distant metastatic lesions that occurred at diag-
nosis or recurrence had either pure NEC or coexisting com-
ponent(s). Therefore, the NE component of MiNEN is most
likely the primary cause of the malignancy of the disease,
regardless of the proportion of the two components in the
primary tumor. We recommend that patients with MiNEN undergo aggressive multidisciplinary oncologic management, and an optimal modality should be established based on the NEC component.

5 CONCLUSION

Collectively, MiNEN is a heterogeneous disease that has been overlooked. Regional lymph nodes metastasis might affect the proportion of different components in the primary tumor, while distant metastasis is primarily caused by NE or coexisting components. The NE component primarily affects invasion or recurrence in distant metastases and should be considered when deciding the appropriate treatment for MiNEN. Moreover, an NE component of <30% volume of the mixed primary tumor can still metastasize and affect prognosis, indicating that the diagnosis criteria for MiNEN should be further investigated.

ACKNOWLEDGMENT

We thank all of our colleagues at the Peking University Cancer Hospital for constructive discussions and technical assistance.

CONFLICT OF INTEREST

The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

AUTHOR CONTRIBUTIONS

Panpan Zhang, Zhongwu Li and Ming Lu designed the research. Panpan Zhang wrote the manuscript and analyzed the data. Zhongwu Li, Jie Li, Jian Li, Xiaotian Zhang, Zhihao Lu, Yu Sun, Yan Li, Jun Zhou, Xicheng Wang, Zhi Peng and Lin Shen collected the data and technical information. Ming Lu reviewed and helped revise the manuscript. All authors approved the final proof.

DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID

Panpan Zhang https://orcid.org/0000-0002-8187-6455
Jian Li https://orcid.org/0000-0002-9333-3255
Jun Zhou https://orcid.org/0000-0003-0570-1730
Zhi Peng https://orcid.org/0000-0003-4063-9813
Lin Shen https://orcid.org/0000-0003-1134-2922

REFERENCES

1. Cordier R. Les cellules argentaffines dans les tumeurs intestinales. Arch Int Med Exp. 1924;1(5).
2. Lewin K. Carcinoid tumors and the mixed (composite) glandular-endocrine cell carcinomas. Am J Surg Pathol. 1987;11(Suppl 1):71-86.
3. Bosman F. World Health Organization International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 2010:160-166.
4. de Mestier L, Cros J, Neuzillet C, et al. Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms. Neuroendocrinology. 2017;105(4):412-425. https://doi.org/10.1159/000475527.
5. Jiang S-X, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I. Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol. 2006;30(8):945-953.
6. Park JY, Ryu M-H, Park YS, et al. Prognostic significance of neuroendocrine components in gastric carcinomas. Eur J Cancer. 2014;50(16):2802-2809.
7. Zhang W, Xiao W, Ma H, Sun M, Chen H, Zheng S. Neuroendocrine liver metastasis in gastric mixed adenoneuroendocrine carcinoma with trilineage cell differentiation: a case report. Int J Clin Exp Pathol. 2014;7(9):6333.
8. Xenaki S, Lasithiotakis K, Andreou A, et al. A rare case of mixed neuroendocrine tumor and adenocarcinoma of the pancreas. Case Rep Surg. 2016;2016:1-4.
9. Max N, Rothe A, Langner C. Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: a case report. Mol Clin Oncol. 2016;5(1):95-98.
10. Zhang L, DeMay RM. Cytological features of mixed adenoneuroendocrine carcinoma of the ampulla: two case reports with review of literature. Diagn Cytopathol. 2014;42(12):1075-1084.
11. Watanabe J, Suwa Y, Ota M, et al. Clinicopathological and prognostic evaluations of mixed adenoneuroendocrine carcinoma of the colon and rectum: a case-matched study. Dis Colon Rectum. 2016;59(12):1160-1167.
12. Chen M-H, Kuo Y-J, Yeh Y-C, et al. High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms. J Chin Med Assoc. 2015;78(8):454-459.
13. Brathwaite S, Rock J, Yearsley MM, et al. Mixed adenoneuroendocrine carcinoma: an aggressive clinical entity. Ann Surg Oncol. 2016;23(7):2281-2286.
14. Lee EJ, Park SM, Maeng L, Lee A, Kim KM. Composite glandular-endocrine cell carcinomas of the stomach: clinicopathologic and methylation study. Ampnis. 2005;113(9):569-576.
15. Lee HH, Jung CK, Jung ES, Song KY, Jeon HM, Park CH. Mixed exocrine and endocrine carcinoma in the stomach: a case report. J Gastric Cancer. 2011;11(2):122-125.
16. Jain D, Eslami-Varzaneh F, Takano AM, et al. Composite glandular and endocrine tumors of the stomach with pancreatic acinar differentiation. Am J Surg Pathol. 2005;29(11):1524-1529.
17. Mondolfi AEP, Slova D, Fan W, et al. Mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: a possible stem cell tumor? Pathol Int. 2011;61(10):608-614.
18. Scardoni M, Vittoria E, Volante M, et al. Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components. *Neuroendocrinology*. 2014;100(4):310-316. https://doi.org/10.1159/000369071.

19. Vanacker L, Smeets D, Hoorens A, et al. Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment. *Anticancer Res*. 2014;34(10):5517-5521.

20. Furlan D, Sahnane N, Mazzoni M, et al. Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum. *Virchows Arch*. 2013;462(1):47-56. https://doi.org/10.1007/s00428-012-1348-2.

21. Tanaka T, Kaneko M, Nozawa H, et al. Diagnosis, assessment, and therapeutic strategy for colorectal mixed adenoneuroendocrine carcinoma. *Neuroendocrinology*. 2017;105(4):426-434.

**How to cite this article:** Zhang P, Li Z, Li J, et al. Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm. *Cancer Med*. 2021;00:1–9. https://doi.org/10.1002/cam4.4031